Stereotactic body radiotherapy boost toxicity for high and intermediate-risk prostate cancer: Report of a multi-institutional study.

Irving D. Kaplan,Limor Appelbaum,Nima Aghdam,Jarad Martin,Mark Sidhom,David Pryor,Joseph A. Aronovitz,Anand Mahadevan,Kevin F. Kennedy,Sean P. Collins

Stereotactic body radiotherapy boost toxicity for high and intermediate-risk prostate cancer: Report of a multi-institutional study.

2020

Irving D. Kaplan
Limor Appelbaum
Nima Aghdam
Jarad Martin
Mark Sidhom
David Pryor
Joseph A. Aronovitz
Anand Mahadevan
Kevin F. Kennedy
Sean P. Collins

365Background: External beam radiation therapy (EBRT) with androgen suppression (AS) and low dose rate (LDR)brachytherapy boost has been shown to improve biochemical progression free survival in un...

Keywords:

Oncology
Prostate cancer
Toxicity
intermediate risk
Pathology
Radiation therapy
Internal medicine
Medicine
Androgen suppression
Brachytherapy
low dose rate
stereotactic body radiotherapy
biochemical progression

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations